Literature DB >> 34333753

Integrated backscatter-intravascular ultrasound and modification of plaque during excimer laser coronary angioplasty.

Satoru Sasaki1, Kenji Nakajima2, Keizo Watanabe3, Yudai Nozaki3, Tadashi Yuguchi2, Hiroyuki Sano2, Ryo Matsutera2, Naoki Murai2, Hiroaki Abe2, Hideyuki Takaoka2.   

Abstract

This study aims to test the hypothesis that the effect of excimer laser coronary angioplasty (ELCA) not only vaporizes thrombi and their underlying coronary plaque, it also changes their quality. We performed a series of cross-sectional analyses in 52 lesions in 51 patients before and after ELCA with integrated backscatter-intravascular ultrasound (IB-IVUS). The constituent parts of the plaque can be assessed by IB-IVUS (i.e., calcified, fibrous, lipid) according to integrated backscatter values. Minimum lumen diameter, lumen volume and vessel volume expanded after ELCA, while plaque volume did not significantly decrease. There was also a decrease of 'lipid' component (35.4-30.3%, P < 0.001) and an increase of IB-IVUS-derived 'fibrous' part (34.5-38.3%, P < 0.001). These results may help in understanding plaque change after ELCA. Excimer laser coronary angioplasty seems to contribute to the modification of coronary plaque composition in addition to debulking it.
© 2021. The Author(s).

Entities:  

Keywords:  Excimer laser coronary angioplasty; Integrated backscatter-intravascular ultrasound; Plaque modification

Mesh:

Year:  2021        PMID: 34333753      PMCID: PMC8926960          DOI: 10.1007/s12928-021-00797-0

Source DB:  PubMed          Journal:  Cardiovasc Interv Ther        ISSN: 1868-4297


Introduction

Excimer laser coronary angioplasty (ELCA) is reported to be useful in percutaneous interventions [1, 2]. This method of atherectomy uses the energy of 308-nm wavelet ultraviolet from excited xenon chloride molecules. The laser breaks the molecular bonds of the plaque tissue and vaporizes the intracellular water, vapor bubbles then break down the radiated tissue [3]. In our clinical experience, we often observed that the media of the target vessel often seems to have higher echogenicity in intravascular ultrasound (IVUS) after ELCA. To our knowledge, however, this phenomenon has not been widely reported. To evaluate the effect of ELCA on the plaque in media of the coronary artery, we used integrated backscatter-intravascular ultrasound (IB-IVUS). We hypothesized that the effect of ELCA might be in part due to debulking the thrombus and its underlying plaque tissue, but also by its modification. We used IB-IVUS to distinguish between different tissue characteristics.

Methods

Study design and population

We included patients aged ≥ 20 years with coronary artery disease, and who underwent percutaneous coronary intervention (PCI) in our hospital between August 2018 and March 2020. Patients were included depending on several characteristics. Those with > 90% stenosis on angiogram were included, regardless of symptoms. If patients had > 70% stenosis with symptoms they were also included, as were patients diagnosed with ischemia according to treadmill testing and/or physiological estimation by pressure wire, regardless of the presentation of symptoms. In all cases, the targets were de novo lesions and ELCA was used within the procedures. The lesions were estimated before and after ELCA by IVUS using 60 MHz ultrasound signals (VISICUBE, Terumo, Tokyo, Japan), and all could be visualized by IB-IVUS. Cases were excluded if the patient required cardiopulmonary resuscitation, if the target lesion was restenosis, if PCI was to de novo branch lesions in which the main vessel had been revascularized before, or if balloon angioplasty was performed between the IVUS procedures being compared. The study was approved by the Takatsuki General Hospital Institutional Review Board. The need for individual patient consent was waived because data were collected retrospectively and anonymized. The study flowchart is shown in Supplementary Fig. 1.

Definition

Diagnosis of ST-segment elevation myocardial infarction (STEMI) was as previously proposed [4]. Diagnosis of unstable angina pectoris/non-ST-segment elevation myocardial infarction (UAP/NSTEMI) requires symptoms consistent with cardiac ischemia and evident stenosis shown by coronary angiography with ST-segment deviations in ECG at rest. It must not meet the STEMI criteria. Exertional angina pectoris and silent ischemic heart disease are both considered to be stable angina pectoris (AP) and are diagnosed by treadmill exercise test [5], or by physiological examination with pressure wire during coronary angiography [6]. Procedural success was defined as a final reduction of lumen diameter stenosis to < 30% and thrombolysis in myocardial infarction (TIMI) 3 flow in the absence of major in-hospital complications (death, emergency bypass surgery, novel development of myocardial infarction and target vessel revascularization).

Coronary intervention

We typically pretreated patients with dual antiplatelet therapy: 100 mg of aspirin and a P2Y12 inhibitor of either 75 mg of clopidogrel or 3.75 mg of prasugrel daily for at least five days. If these were not prescribed (e.g., in emergent cases), loading dose of 200 mg of aspirin, 300 mg clopidogrel, or 20 mg prasugrel was administered before the coronary intervention. Intravenous heparin was administered during the index procedure to maintain an activated clotting time > 250 s. Glycoprotein IIa/b inhibitors were not used in any cases. When angiogram or IVUS revealed thrombus on the target lesion, a thrombus aspiration device was used first. After IVUS analysis, ELCA was then used at the physicians’ discretion. The pulse-wave xenon chloride excimer laser generator (CVX-300P, Spectranetics, Colorado Spring, Colorado) operates at 308-nm wavelength. Pulse duration is 135 ns and the output is 165 mJ/pulse. Initial energy parameters were set at a fluence of 45 mJ/mm2 and 25 Hz, which was increased if the debulking effect was insufficient. The catheter (ELCA, Spectranetics, Colorado Spring, CO) size was chosen from a concentric type of 0.9, 1.4, 1.7, or 2.0 mm, or eccentric type of 1.7 or 2.0 mm in diameter according to the reference of the vessel size and plaque eccentricity. During ablation procedures, saline was injected [7], and the laser catheter was advanced as slowly as 0.5 mm/s [8].

Quantitative coronary angiography

Angiographic images were analyzed using commercially available software (QAngio XA7.3, Medis Medical Imaging System B.V., Leiden, the Netherlands). We recorded the minimal lumen diameter, reference vessel diameter, percentage of plaque area, and lesion length of each lesion. If lesion length and reference vessel diameter could not be calculated in an occluded vessel, we used the first angiogram in which the lumen was recanalized after the thrombus aspiration.

IVUS analysis

We administered intracoronary nitroglycerin before the image acquisition at between 100 and 250 μg, depending on the systemic blood pressure. We performed IVUS assessments before and after laser angioplasty. Using the motorized transducer pullback system, the 3.0 Fr IVUS imaging catheter (Altaview, Terumo, Tokyo, Japan) incorporated a 60-MHz phased array transducer (VISICUBE, Terumo, Tokyo, Japan). Offline IVUS images were analyzed by independent investigators who were unaware of patient clinical characteristics. Quantitative IVUS analyses were performed according to the expert consensus document from the Japanese Association of Cardiovascular Intervention and Therapeutics [9]. External elastic membrane, lumen and intima-media complex areas were obtained by manual contour detection. To illustrate the tissue characteristics of the lesion, color-coded maps were constructed for each 0.1–0.5 mm slice. Lumen area, lumen volume, vessel volume, and total plaque volume, and the percentage of each plaque component were automatically calculated. Compositional tissue characteristic areas were expressed as colors according to integrated backscatter values, as previously described (red: calcification, yellow: dense fibrosis, green: fibrosis, blue and purple: lipid pool) [10, 11].

Statistical analyses

All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [12]. Categorical variables are presented as frequencies with percentage and continuous variables are presented as mean ± standard deviation. Patient data were analyzed before and after ELCA with paired t test. Categorical variables were compared using the chi-square or Fisher’s exact test as appropriate. A two-sided P value < 0.05 was considered to be statistically significant.

Results

In line with the current guidelines, PCI for de novo lesions using ELCA and IB-IVUS was performed in our hospital for 72 lesions in 71 patients during the study period. We excluded 20 cases; 14 due to impaired IVUS analysis, four because of lost data and two because of inadequate procedure (balloon angioplasty performed between the index IVUS pullbacks).

Representative case

A representative STEMI case is shown in Fig. 1. A 59-year-old male with hypertension and hyperlipidemia was admitted to our hospital with chest pain. Coronary angiography showed severe stenosis with flow limitation in a branch of left circumflex. ELCA was used, followed by balloon angioplasty and stenting of a sirolimus-eluting stent. Conventional IVUS showed that the minimum lumen area (1.34–2.47 mm2) and the lumen volume (17.8–24.3 mm3) increased during ELCA. IB-IVUS, meanwhile, additionally revealed that plaque composition shifted from being mainly purple-colored (lipid) to being green-colored (IB-IVUS-derived fibrous); purple-colored area, 30.7% to 23.6% green-colored area 39.2% to 44.7%.
Fig. 1

Angiography, conventional IVUS, IB-IVUS images and parameters before and after ELCA of a representative case. Angiography before ELCA (above, left), conventional and IB-IVUS images before ELCA (above middle), IVUS parameters before ELCA (above right). Angiography after ELCA (below, left), conventional and IB-IVUS images after ELCA (below, middle), IVUS parameters after ELCA (below, right). ELCA excimer laser coronary angioplasty. IB-IVUS integrated backscatter-intravascular ultrasound. IVUS intravascular ultrasound

Angiography, conventional IVUS, IB-IVUS images and parameters before and after ELCA of a representative case. Angiography before ELCA (above, left), conventional and IB-IVUS images before ELCA (above middle), IVUS parameters before ELCA (above right). Angiography after ELCA (below, left), conventional and IB-IVUS images after ELCA (below, middle), IVUS parameters after ELCA (below, right). ELCA excimer laser coronary angioplasty. IB-IVUS integrated backscatter-intravascular ultrasound. IVUS intravascular ultrasound

Patient characteristics

Table 1 shows clinical characteristics of the patients in this study. The mean age was 68.3 years, 76% were men, and 25% had diabetes mellitus. STEMI was diagnosed in 50% of patients. Laboratory data showed the average estimated glomerular filtration rate 73 mL/min/1.73 m2, low-density lipoprotein cholesterol level 108 mg/dL, hemoglobin A1c 6.3%. On admission, 41% of the patients took aspirin and 37% took P2Y12 receptor inhibitor. All patients who did not take these antiplatelet drugs were administered a loading dose before index PCIs. Echocardiography showed that the average left ventricular ejection fraction of each patient was preserved at 54 ± 11%.
Table 1

Patient characteristics

n = 51
Age (years)68.3 ± 12.3
Male39 (76%)
BMI23.6 ± 3.6
Clinical diagnosis
 STEMI26 (50%)
 UAP/NSTEMI13 (25%)
 Stable AP13 (25%)
 Hypertension33 (65%)
 Hyperlipidemia39 (76%)
 Diabetes mellitus13 (25%)
 Smoking31 (61%)
 Family history of CAD11 (22%)
 Chronic kidney disease12 (24%)
 Old myocardial infarction1 (2%)
 Prior PCI3 (6%)
 Prior CABG0 (0%)
 Hemodialysis1 (2%)
 LVEF (%)54 ± 11
 Serum creatinine (mg/dL)0.97 ± 0.62
 Estimated GFR (mL/min/1.73 m2)72.9 ± 28.8
 LDL-C (mg/dL)108 ± 41
 HDL-C (mg/dL)57 ± 18
 HbA1c (%)6.3 ± 1.5
Medication at admission
 Aspirin21 (41%)
 P2Y12 receptor inhibitor19 (37%)
 ACE-I/ARB18 (35%)
 Beta-blocker7 (14%)
 Calcium channel blocker20 (39%)
 Statin20 (39%)
 Insulin4 (8%)

Data are expressed as the mean ± standard deviation or the number (percentage)

ACE-I angiotensin-converting enzyme inhibitor; AP angina pectoris; ARB angiotensin receptor blocker; BMI body mass index; CABG coronary artery bypass grafting; CAD coronary artery disease; GFR glomerular filtration rate; HbA1c hemoglobin A1c; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; LVEF left ventricular ejection fraction; OMI old myocardial infarction; PCI percutaneous coronary intervention; STEMI ST-segment elevation myocardial infarction; UAP/NSTEMI unstable angina pectoris/non-ST-segment elevation myocardial infarction

Patient characteristics Data are expressed as the mean ± standard deviation or the number (percentage) ACE-I angiotensin-converting enzyme inhibitor; AP angina pectoris; ARB angiotensin receptor blocker; BMI body mass index; CABG coronary artery bypass grafting; CAD coronary artery disease; GFR glomerular filtration rate; HbA1c hemoglobin A1c; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; LVEF left ventricular ejection fraction; OMI old myocardial infarction; PCI percutaneous coronary intervention; STEMI ST-segment elevation myocardial infarction; UAP/NSTEMI unstable angina pectoris/non-ST-segment elevation myocardial infarction

Lesion characteristics

Lesion characteristics are shown in Table 2. Target vessels were left anterior descending arteries in 50% of cases. There were 21 cases (40%) without any flow limitation before intervention, and the target vessel was totally occluded in 12 cases (23%). There were 22 cases with evident thrombus localized in the target vessels (i.e., TIMI thrombus scale Grade 2–5) [13].
Table 2

Lesion characteristics

n = 52
Lesion location
 LMT0 (0%)
 LAD/Dg26 (50%)/1 (2%)
 LCx5 (10%)
 RCA20 (38%)
TIMI flow
 321 (40%)
 216 (31%)
 13 (6%)
 012 (23%)
TIMI thrombus grade
 09 (17%)
 121 (40%)
 23 (6%)
 34 (8%)
 43 (6%)
 512 (23%)
ACC/AHA type
 A10 (19%)
 B110 (19%)
 B220 (38%)
 C10 (19%)
 Non-measurable2 (4%)

Data are expressed as the number (percentage)

ACC/AHA American College of Cardiology/American Heart Association; Dg diagonal branch; LAD left anterior descending artery; LCx left circumflex artery; LMT left main trunk; RCA right coronary artery; TIMI thrombolysis in myocardial infarction

Lesion characteristics Data are expressed as the number (percentage) ACC/AHA American College of Cardiology/American Heart Association; Dg diagonal branch; LAD left anterior descending artery; LCx left circumflex artery; LMT left main trunk; RCA right coronary artery; TIMI thrombolysis in myocardial infarction

Procedure and angiographic outcomes

The procedure and its outcomes are depicted in Table 3. Relatively smaller catheter sizes (1.4 mm, 0.9 mm) were used in 33 cases (63%). Stent implantation was performed in 32 cases (62%), while all cases used adjunctive balloon angioplasty. Final TIMI 3 flow was achieved in 51 cases (98%), and the procedure was successful in 43 cases (83%). Cases of procedural failure consist of one (typical) case with remaining coronary dissection at the distal edge of the stent, and seven (atypical) cases of paclitaxel drug-coated balloon alone angioplasty with remaining intermediate stenosis. In these cases, stent-free strategy was preferred by PCI operators because of the clinical backgrounds. Clinically, there was no target vessel revascularization and no major adverse cardiac events in any of the seven cases after the index PCI during 234 to 596 days observational periods (data not shown).
Table 3

Procedure and angiographic outcomes

n = 52
Laser catheter size
 1.7 mm19 (37%)
 1.4 mm23 (44%)
 0.9 mm10 (19%)
Laser passes2 ± 1 (1–5)
Laser output (mJ/mm2)45–60
Laser pulses delivered1522 ± 1022 (375–5395)
Adjunctive balloon angioplasty52 (100%)
Stent implantation32 (62%)
Final TIMI 3 flow51 (98%)
Procedural success43 (83%)

Data are expressed as the number (percentage), the mean ± standard deviation (minimum to maximum)

TIMI thrombolysis in myocardial infarction

Procedure and angiographic outcomes Data are expressed as the number (percentage), the mean ± standard deviation (minimum to maximum) TIMI thrombolysis in myocardial infarction ELCA followed by angioplasty or stent implantation resulted in the increased minimum lumen (stent) diameter in this study (Table 4). According to quantitative coronary angiogram analysis, minimum lumen diameter expanded (0.81–2.33 mm), and percentage of diameter stenosis decreased (69.7–18.6%).
Table 4

Quantitative angiographic results before and after ELCA

Pre-ELCA (n = 50)Post-ELCA (n = 20)Final (n = 52)
MLD (mm)0.81 ± 0.401.21 ± 0.482.33 ± 0.48
Reference (mm)2.65 ± 0.622.57 ± 0.632.88 ± 0.40
% DS (%)69.7 ± 12.351.8 ± 17.618.6 ± 12.5
Lesion length (mm)14.4 ± 8.3
Acute gain (mm)0.33 ± 0.451.54 ± 0.58

Data are expressed as the mean ± standard error

ELCA excimer laser coronary angioplasty; MLD minimum lumen diameter; %DS percentage of diameter stenosis

Quantitative angiographic results before and after ELCA Data are expressed as the mean ± standard error ELCA excimer laser coronary angioplasty; MLD minimum lumen diameter; %DS percentage of diameter stenosis Quantitative parameters of conventional IVUS are shown in Table 5. Minimum lumen area, lumen volume, and the vessel volume increased significantly after ELCA, while plaque volume did not change. According to subgroup analysis, lumen volume increased in STEMI groups, but did not in the stable AP group. Plaque volume, meanwhile, did not change significantly in any subgroups (Table 5). Assessment of IB-IVUS revealed a decrease in the ratio of purple-colored area (lipid plaque, concealed component), while the green area (IB-IVUS-derived fibrous plaque) increased significantly (Fig. 2). This phenomenon was consistent across all subgroups (Figs. 3, 4, 5). The change in volume of each component corresponded with its ratio. (Supplementary Fig. 2-1, 2-2a, 2b, 2c).
Table 5

Quantitative parameters of conventional IVUS

Pre-ELCAPost-ELCAP
All cases
 MLA (mm2)1.65 ± 0.072.25 ± 0.14 < 0.001
 Lumen volume (mm3)43.7 ± 4.054 ± 4.7 < 0.001
 Vessel volume (mm3)200 ± 19207 ± 190.001
 Plaque volume (mm3)156 ± 16153 ± 150.09
STEMI cases
 MLA (mm2)1.64 ± 0.132.16 ± 0.15 < 0.001
 Lumen volume (mm3)40.8 ± 4.250.1 ± 4.7 < 0.001
 Vessel volume (mm3)193.7 ± 21.2202.4 ± 22.50.001
 Plaque volume (mm3)152.9 ± 19.0152.3 ± 19.10.83
UAP/NSTEMI cases
 MLA (mm2)1.58 ± 0.132.23 ± 0.210.02
 Lumen volume (mm3)46.8 ± 9.463.5 ± 13.60.05
 Vessel volume (mm3)216 ± 47.3227.3 ± 50.40.04
 Plaque volume (mm3)169.2 ± 40.0163.8 ± 37.10.21
Stable AP cases
 MLA (mm2)1.75 ± 0.142.45 ± 0.430.08
 Lumen volume (mm3)46.4 ± 10.452.1 ± 9.70.10
 Vessel volume (mm3)195.4 ± 43.1194.8 ± 40.90.90
 Plaque volume (mm3)146.7 ± 33.2142.4 ± 31.80.06

Data are expressed as the mean ± standard error

ELCA excimer laser coronary angioplasty; MLA minimum lumen area; STEMI ST-segment elevation myocardial infarction; UAP/NSTEMI unstable angina pectoris/non-ST-segment elevation myocardial infarction

Fig. 2

Change of plaque component observed by IB-IVUS

Fig. 3

Change of plaque component observed by IB-IVUS in STEMI cases

Fig. 4

Change of plaque component observed by IB-IVUS in UAP/NSTEMI cases

Fig. 5

Change of plaque component observed by IB-IVUS in stable AP cases

Quantitative parameters of conventional IVUS Data are expressed as the mean ± standard error ELCA excimer laser coronary angioplasty; MLA minimum lumen area; STEMI ST-segment elevation myocardial infarction; UAP/NSTEMI unstable angina pectoris/non-ST-segment elevation myocardial infarction Change of plaque component observed by IB-IVUS Change of plaque component observed by IB-IVUS in STEMI cases Change of plaque component observed by IB-IVUS in UAP/NSTEMI cases Change of plaque component observed by IB-IVUS in stable AP cases

Discussion

This is the first report in which quantitative or qualitative changes in coronary plaque have been estimated by IB-IVUS during ELCA, and it presents two major findings. First, after ELCA, the vessel volume and lumen volume increased, confirming the results of a previous study in 1995 [14]. Lumen enlargement was reported to be gained by tissue ablation and/or vessel expansion without calcium ablation, but there were no predictors of which factor contributed to the lumen enlargement in angiographic or IVUS findings. In our study, plaque volume was not decreased with significant difference. Lumen enlargement and vessel expansion without calcium ablation were found mainly in cases of STEMI, and we suggest the same could be said of focal tissue ablation. The reason for enlargement of the lumen and the vessel being observed in the STEMI group but not in the stable AP group is unclear. Vessel compliance and plaque morphology may be different between these two groups. The difference in morphological pattern between the acute coronary syndrome group and the stable AP group is shown in Figs. 2, 3, 4, and 5. A second finding was that there was a decrease of purple-colored areas (lipid tissue) in color maps of IB-IVUS, but an increase of green-colored areas (fibrous tissue) after ELCA. This is interesting phenomenon because there was no statistically significant decrease in plaque volume. From a biochemical point of view, it is difficult to believe that lipid-rich plaque changed into fibrous plaque, it is easier to assume that lipid is modified with high echogenicity. Such modification was not shown, however, in a previous report of ex vivo histological assessment in microscopy, in which excimer laser did not injure aortic media postmortem [15]. This modification of lipid plaque has thus not yet been histologically identified. How the effect of excimer laser results in this alteration is unclear. Although harmful damage has not been reported, change of up to approximately 10 °C has been observed in vitro assays [16], so the change may have arisen from thermal effect. We believe that the effect of ELCA was solely dependent upon the increase of lumen volume by plaque debulking. Lumen enlargement by vessel volume expansion and morphological change of intima–media complex in coronary arteries were implied by our study to be other effects of ELCA. PCI operators sometimes encounter cases in which the lumen is not satisfactorily enlarged after ELCA. There is hesitation to increase the energy setting of ELCA owing to the potential for coronary perforation. We may conclude that ELCA reaches its optimal result when the green-colored area by IB-IVUS increased after ELCA. Clarification of the feasibility of this conservative method by comparison of this conservative ablation method with aggressive ablation (gaining lumen volume) methods will be the subject of further studies.

Limitations

This study has some limitations; it is a single-center retrospective study with a small patient population, and it is not a controlled trial, so the results observed by IB-IVUS cannot be gained just by ELCA. There were four cases in which IB-IVUS examination was performed before and after angioplasty prior to ELCA, implying that the purple-colored area decreased only balloon angioplasty (Supplementary table). Further study is, therefore, essential for comparison between the ELCA group and non-ELCA group. Although ELCA was expected to be used to debulk thrombi and plaque, there was no significant decrease in plaque volume in this study. This means that ELCA may be insufficient in this study. It is, however, interesting that the morphologic pattern of IB-IVUS shifted despite the insufficient debulking effect in volume. Distinguishing thrombi from medial plaque is also difficult, especially in STEMI cases. Thrombi tend to be categorized as blue- or purple-colored components (lipid tissue) and can hide underlying plaque, which may result in underestimation of other categories. Future studies should aim to pathologically solve this intrinsic limitation of IVUS.

Conclusion

Excimer laser coronary angioplasty seems to contribute to the modification of coronary plaque composition in addition to debulking it. These results may illuminate understanding about plaque change after ELCA. Below is the link to the electronic supplementary material. Supplementary file1 (JPG 123 KB) Supplementary file2 (JPG 169 KB) Supplementary file3 (JPG 168 KB) Supplementary file4 (JPG 174 KB) Supplementary file5 (JPG 167 KB) Supplementary file6 (JPG 94 KB)
  16 in total

1.  Exercise standards for testing and training: a scientific statement from the American Heart Association.

Authors:  Gerald F Fletcher; Philip A Ades; Paul Kligfield; Ross Arena; Gary J Balady; Vera A Bittner; Lola A Coke; Jerome L Fleg; Daniel E Forman; Thomas C Gerber; Martha Gulati; Kushal Madan; Jonathan Rhodes; Paul D Thompson; Mark A Williams
Journal:  Circulation       Date:  2013-07-22       Impact factor: 29.690

2.  Tissue characterization of coronary plaques: comparison of integrated backscatter intravascular ultrasound with virtual histology intravascular ultrasound.

Authors:  Munenori Okubo; Masanori Kawasaki; Yoshiyuki Ishihara; Urara Takeyama; Shinji Yasuda; Tomoki Kubota; Shinichiro Tanaka; Takahiko Yamaki; Shinsuke Ojio; Kazuhiko Nishigaki; Genzou Takemura; Masanao Saio; Tsuyoshi Takami; Hisayoshi Fujiwara; Shinya Minatoguchi
Journal:  Circ J       Date:  2008-08-28       Impact factor: 2.993

3.  Effect of intracoronary saline infusion on dissection during excimer laser coronary angioplasty: a randomized trial. The Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Investigators.

Authors:  L I Deckelbaum; M K Natarajan; J A Bittl; K Rohlfs; J Scott; R Chisholm; K A Bowman; B H Strauss
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

4.  2018 ESC/EACTS Guidelines on myocardial revascularization.

Authors:  Franz-Josef Neumann; Miguel Sousa-Uva; Anders Ahlsson; Fernando Alfonso; Adrian P Banning; Umberto Benedetto; Robert A Byrne; Jean-Philippe Collet; Volkmar Falk; Stuart J Head; Peter Jüni; Adnan Kastrati; Akos Koller; Steen D Kristensen; Josef Niebauer; Dimitrios J Richter; Petar M Seferović; Dirk Sibbing; Giulio G Stefanini; Stephan Windecker; Rashmi Yadav; Michael O Zembala
Journal:  EuroIntervention       Date:  2019-02-20       Impact factor: 6.534

5.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis
Journal:  Circulation       Date:  2012-08-24       Impact factor: 29.690

6.  Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.

Authors:  C M Gibson; J A de Lemos; S A Murphy; S J Marble; C H McCabe; C P Cannon; E M Antman; E Braunwald
Journal:  Circulation       Date:  2001-05-29       Impact factor: 29.690

7.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  Mechanisms of lumen enlargement after excimer laser coronary angioplasty. An intravascular ultrasound study.

Authors:  G S Mintz; J A Kovach; S P Javier; A D Pichard; K M Kent; J J Popma; L F Salter; M B Leon
Journal:  Circulation       Date:  1995-12-15       Impact factor: 29.690

9.  Indications and outcomes of excimer laser coronary atherectomy: Efficacy and safety for thrombotic lesions-The ULTRAMAN registry.

Authors:  Masami Nishino; Naoki Mori; Shin Takiuchi; Daisuke Shishikura; Naofumi Doi; Toru Kataoka; Takayuki Ishihara; Noriyuki Kinoshita
Journal:  J Cardiol       Date:  2016-07-02       Impact factor: 3.159

Review 10.  An integrated backscatter ultrasound technique for the detection of coronary and carotid atherosclerotic lesions.

Authors:  Masanori Kawasaki
Journal:  Sensors (Basel)       Date:  2015-01-07       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.